Introduction {#S1}
============

*Mycobacterium tuberculosis* (*M.tb*) causes significant morbidity and mortality around the world every year. Tuberculosis (TB) is now the leading cause of death attributed to a single infectious organism, surpassing the human immunodeficiency virus ([@R1]). Mathematical models predict approximately 1.7 billion individuals, a quarter of the world\'s population, to be infected with *M.tb* in a latent state serving as a large reservoir for the disease ([@R2]). Current chemotherapy against TB, though effective, has led to the rise of drug resistant strains making it more difficult to curtail this disease ([@R1]). Thus, the best approach to contain, and potentially eradicate, TB may lie in the development of an effective vaccine. *Mycobacterium bovis* Bacille de Calmette *et* Guérin (BCG) is the only vaccine currently supported by the World Health Organization for the prevention of TB. However, the efficacy of BCG at preventing pulmonary TB is highly variable ([@R3];[@R4]), and its protective immunity in humans only appears to last for 10-15 years ([@R5]). Despite many efforts to develop new effective TB vaccines over the last few decades, these approaches have resulted in little success ([@R3];[@R4];[@R6]).

During the natural course of infection with *M.tb*, bacilli are inhaled and deposited in the alveolar sacs of the lung ([@R7]) where they are bathed in alveolar lining fluid (ALF) ([@R8]). ALF is composed of surfactant lipids and its associated proteins, as well as of an aqueous hypophase rich in innate host defense molecules such hydrolytic enzymes ([@R9]), complement proteins ([@R10]), surfactant proteins A and D ([@R11]), and immunoglobulins ([@R12]). We have shown that interaction with ALF attenuates *M.tb* pathogenicity *in vitro* ([@R9];[@R13];[@R14]), likely due to the action of hydrolytic enzymes removing cell wall peripheral lipids such as mannose-capped lipoarabinomannan and trehalose dimycolate ([@R9]). Thus, exposure to human ALF modifies *M.tb*, reducing virulence factors and exposing new antigenic motifs on its surface prior to encountering and infecting host cells. Such changes modify uptake and phagocytosis by host cells ([@R9];[@R13];[@R14]), which initiate innate immune responses to *M.tb* that we consider to be influential in the generation of appropriate adaptive immune responses *in vivo*. It is therefore plausible to hypothesize that immunogenic cell wall motifs and virulence factors associated with *M.tb* are affected by *M.tb*\'s contact with ALF during infection.

In this study we determined whether the underlying mechanism behind poor BCG efficacy may be due to discrepancies associated with the natural route of infection with *M.tb* via the lung, *vs.* inoculation with BCG via the skin. We hypothesized that ALF-exposed BCG would generate an immune response against similar motifs that are accessible to the immune system during *M.tb* infection in the lung, resulting in improved control of *M.tb* during challenge. We identified differences in immune responses to ALF-exposed BCG vaccination in the lung, particularly within the CD8^+^ T cell subset. When challenged with *M.tb*, ALF-exposed BCG vaccination led to a significant decrease in *M.tb* bacterial burden, reduced pulmonary inflammation, and extended survival in C57BL/6J mice. The reduction in bacterial burden was dependent on CD8^+^ T cell responses and was associated with increased IFNγ in the lung. Hence, we provide proof of principle that changes on the BCG cell wall surface, akin to the ones observed by *M.tb* after exposure to human ALF, have the potential to generate superior host immune responses and induce better protection against infection. Our studies highlight the importance of considering the properties of human ALF when developing an effective vaccine against TB.

Results {#S2}
=======

Vaccination with ALF-exposed BCG reduces bacterial burden in the lung and spleen and extends survival of mice {#S3}
-------------------------------------------------------------------------------------------------------------

C57BL/6J mice were vaccinated with either vehicle (mock-vaccinated; no BCG), NaCl- exposed BCG, or ALF-exposed BCG. Six weeks after vaccination, all groups were infected with a low dose aerosol of ALF-exposed *M.tb* (the same ALF used for BCG vaccination). The outcome of infection with ALF-exposed *M.tb,* in terms of lung bacterial burden, was similar to that of conventional laboratory *M.tb* strains ([supplemental Fig. S1](#SD1){ref-type="supplementary-material"}). ALF-exposed, and not broth grown *M.tb*, was specifically used to model the composition of the *M.tb* cell wall after exposure to human ALF. We observed similar biochemical changes to the BCG cell wall as we observed previously with ALF-exposed *M.tb*, with significant decreases in the amount of trehalose-6,6-dimycolate (TDM) and mannose-capped lipoarabinomannan (ManLAM) remaining on the BCG cell wall ([supplemental Fig. S2 A, B](#SD1){ref-type="supplementary-material"}) ([@R9]). Mice were sacrificed at 14 days post infection (DPI) to specifically address whether ALF-exposed BCG vaccination accelerated the generation of adaptive immunity relative to that observed with BCG ([Fig. 1A](#F1){ref-type="fig"}). As expected, NaCl-exposed BCG vaccination (grey bars) led to an expected moderate, yet significant, reduction in *M.tb* CFU in the lung after only 14 DPI ([Fig. 1B](#F1){ref-type="fig"}) indicating some acceleration of adaptive immunity in BCG vaccinated mice relative to non-vaccinated controls. We did not anticipate a major reduction in *M.tb* CFU in the lung and spleen of BCG vaccinated mice at 14 DPI, as the typical 1.0-log~10~ reduction is not observed until 21-30 DPI ([@R15]). In contrast to mice receiving NaCl-exposed BCG, vaccination with ALF-exposed BCG (black bars) resulted in a superior early reduction in *M.tb* CFU in the lung and a 0.56-log~10~ reduction beyond that afforded by NaCl-exposed BCG. ALF-exposed BCG also conferred an additional 0.8-log~10~ protection against dissemination, as indicated by a significant decrease in bacterial burden in the spleen ([Fig. 1B](#F1){ref-type="fig"}), although CFU were close to the level of accurate detection in this organ. Our data demonstrate that modification of BCG through exposure to ALF can further boost the protective efficacy of BCG *in vivo*, allowing for more rapid control of *M.tb* in the lung as demonstrated by significantly less *M.tb* CFUs at 14 DPI.

We also determined *M.tb* CFU at 250 DPI to assess the ability of ALF-exposed BCG to provide long term control of *M.tb* infection and its impact on development of progressive disease ([@R16]). NaCl-exposed BCG was ineffective at conferring a reduction of *M.tb* CFU in the lung or spleen at 250 DPI ([Fig. 1C](#F1){ref-type="fig"}), similar to several studies that have shown limited long term protection by BCG ([@R17]). In contrast, ALF-exposed BCG vaccination resulted in a significant reduction in *M.tb* CFU at 250 DPI (0.56-log~10~ protection) compared to vehicle control mice ([Fig. 1C](#F1){ref-type="fig"}). This trend was also statistically significant in the spleen ([Fig. 1C](#F1){ref-type="fig"}). Vaccination with ALF-exposed BCG also significantly extended survival ([Fig. 1D](#F1){ref-type="fig"}) to an average of 71.0 weeks, with some mice surviving ∼80.0 weeks, demonstrating superior ability of ALF-exposed BCG to reduce TB severity. The median survival of vehicle-treated mice was 51.0 weeks, which is in line with previously published data ([@R16]) and NaCl-exposed BCG vaccinated mice had a median survival of 64.50 weeks. Overall, exposure of BCG to ALF results in a vaccine that can generate accelerated *M.tb* control ([Fig. 1B](#F1){ref-type="fig"}; early reduction in CFU) combined with the capacity to sustain control of *M.tb* for an extended period of time ([Fig. 1C](#F1){ref-type="fig"}; late reduction in CFUs), which ultimately extends survival by 20.0 weeks relative to non-vaccinated mice (and an additional 6.0 weeks beyond NaCl-exposed BCG) ([Fig. 1D](#F1){ref-type="fig"}).

Vaccination with ALF-exposed BCG reduces pulmonary inflammation {#S4}
---------------------------------------------------------------

To determine the capacity of ALF-exposed BCG to reduce severity of infection and progression of disease, we assessed the degree of tissue involvement through quantification of cellular aggregation relative to the total size of the lung. At 14 DPI ([Fig. 2A](#F2){ref-type="fig"}) we observed no statistically significant difference in tissue involvement between the three groups studied. However, both NaCl-exposed and ALF-exposed BCG vaccinated mice had moderately more cellular infiltration ([Fig. 2B](#F2){ref-type="fig"}), supportive of accelerated immune responses in vaccinated mice. Moreover, mice vaccinated with NaCl-exposed BCG and ALF-exposed BCG visually had equal numbers of inflammatory foci and a similar increase in the number of lymphocytic cuffs in the lung at this time-point ([supplemental Fig. S3A, B](#SD1){ref-type="supplementary-material"}), indicating that the response to *M.tb* infection is accelerated in ALF-exposed BCG vaccinated mice.

At 250 DPI, the lungs of control (vehicle) mice had abundant cellular infiltration and inflammation, with approximately 50% of the entire lung being involved ([Fig. 2A, C](#F2){ref-type="fig"}). Despite a significant extension in survival, the proportion of cellular infiltrate and lung inflammation in NaCl-exposed BCG-vaccinated mice was only moderately reduced relative to control mice ([Fig. 2A, C](#F2){ref-type="fig"}). Both control and NaCl-exposed BCG vaccinated mice had macrophage dominated cellular aggregates in the lung that consumed up to 40-50% of lung space ([Fig. 2A, C](#F2){ref-type="fig"}). In contrast, ALF-exposed BCG vaccinated mice had significantly reduced lung cellular infiltrate relative to control and NaCl-exposed BCG, with approximately 75% of the lung space remaining uninvolved ([Fig. 2C](#F2){ref-type="fig"}). We also observed statistically significant decreases in the number of inflammatory foci and lymphocytic cuffs per lung in animals vaccinated with ALF-exposed BCG ([supplemental Fig. S3A, B](#SD1){ref-type="supplementary-material"}). Furthermore, the smaller cell aggregates within the lung were dominated by lymphocytes ([Fig. 2A, C](#F2){ref-type="fig"}). Therefore, the enhanced control of *M.tb* at 250 DPI and extended survival of ALF-exposed BCG was associated with a significant reduction in lung cellular accumulations, and those cells present in the lung were predominantly of the lymphocytic lineage.

We further validated our findings using the C3HeB/FeJ mouse strain ([supplemental Fig. S3C, D and Fig. S4A-F](#SD1){ref-type="supplementary-material"}), demonstrating that the capacity of ALF-exposed BCG to confer better protection against *M.tb* infection, associated with reduce pulmonary cellular infiltration and inflammation, was common across mice of different genetic backgrounds and *M.tb* susceptibilities. Altogether our data indicate that not only is vaccination with ALF-exposed BCG superior to NaCl-exposed BCG at reducing the bacterial burden in targeted organs but it also can significantly reduce pulmonary inflammation and pathology that is typically associated with morbidity and mortality in *M.tb* infected mice.

Vaccination with ALF-exposed BCG enhances T cell responses in the lung post M.tb challenge {#S5}
------------------------------------------------------------------------------------------

We first determined T cell phenotype and function in the lung after BCG vaccination to elucidate how ALF-exposed BCG can modify the generation of T cell effector and memory responses that would be in the lung during *M.tb* challenge. The total number ([Fig. 3](#F3){ref-type="fig"}) and the frequency ([supplemental Fig. S5](#SD1){ref-type="supplementary-material"}) of CD4^+^ and CD8^+^ T cells in the lungs of mice that received NaCl-exposed or ALF-exposed BCG were equivalent, with no enhancement in the number or frequency of CD4^+^ or CD8^+^ effector and memory T cell subsets, or T cells capable of producing IFNγ. However, a significant increase in CD8^+^ T cells expressing CD69 was observed in the lungs of mice vaccinated with ALF-exposed BCG.

We next characterized T cell responses in the lungs of vehicle, NaCl-, or ALF-exposed BCG vaccinated mice post *M.tb* challenge. Mice were vaccinated, challenged with *M.tb* via aerosol, and sacrificed at 14 DPI to characterize early T cell responses in the lungs. In response to *M.tb* challenge, the total number of CD8^+^ T cells increased significantly in the lung in the ALF-exposed BCG vaccinated mice relative to NaCl-exposed BCG ([Fig. 4A](#F4){ref-type="fig"}). Furthermore, we observed significant changes in the total number ([Fig. 4A-E](#F4){ref-type="fig"}) and frequency ([supplemental Fig. S6](#SD1){ref-type="supplementary-material"}) of CD8^+^ T cell subsets (for gating see [supplemental Fig. S7](#SD1){ref-type="supplementary-material"}). Mice vaccinated with ALF-exposed BCG had significantly increased numbers of CD8^+^ T cells that expressed a memory phenotype (CCR7^neg^CD62L^hi^CD44^hi^) relative to vehicle and NaCl-exposed BCG ([Fig. 4B](#F4){ref-type="fig"}). Mice vaccinated with ALF-exposed BCG also had an increased number of CD8^+^ T cells with the potential to secrete IFNγ, relative to both vehicle and NaCl-exposed BCG ([Fig. 4D](#F4){ref-type="fig"}). We did not observe differences in the number of effector T cells (CCR7^neg^CD62L^lo^CD44^hi^) in the lung ([Fig. 4C](#F4){ref-type="fig"}) and CD69 expression was also unchanged ([Fig. 4E](#F4){ref-type="fig"}).

The total number ([Fig. 4A](#F4){ref-type="fig"}) and frequencies ([supplemental Fig. S6](#SD1){ref-type="supplementary-material"}) of CD4^+^ T cells, CD4^+^ effector, memory, and activated subsets, and CD4^+^ T cells capable of secreting IFNγ was not significantly different between mice vaccinated with ALF-exposed BCG and vehicle control ([Fig. 4A-E](#F4){ref-type="fig"} and [supplemental Fig. S6](#SD1){ref-type="supplementary-material"}). A significant decrease in CD4^+^ T cell frequency for IFNγ was observed between ALF-exposed BCG and NaCl-exposed BCG, but this did not translate to a significant change in total cell number ([Fig. 4D](#F4){ref-type="fig"}). These data indicate that, in contrast to NaCl-exposed BCG, vaccination with ALF-exposed BCG has a significant impact on CD8^+^ T cell numbers in the lung at day 14 DPI, and those cells expressed markers associated with a memory phenotype and had the capacity to secrete IFNγ. These phenotypes were much less apparent in the CD4^+^ T cell subset.

CD8^+^ T cells in the lungs of ALF-exposed BCG vaccinated mice are required for enhanced protection against M.tb {#S6}
----------------------------------------------------------------------------------------------------------------

Having observed significant increases in CD8^+^ T cell numbers and activity in the lung of ALF-exposed BCG vaccinated mice, we explored whether the reduction in bacterial burden ([Fig. 1](#F1){ref-type="fig"}) was directly dependent on CD8^+^ T cells. Mice were vaccinated with vehicle, NaCl- or ALF-exposed BCG. Six weeks later, CD8 neutralizing antibodies or isotype controls were injected one day prior to *M.tb* infection and every four days thereafter. Mice were euthanized at 14 DPI to assess bacterial burden in the lung and spleen. Neutralizing antibodies successfully depleted CD8^+^ T cells from the lung without affecting the total number of CD4^+^ T cells ([Fig. 5A, B](#F5){ref-type="fig"}). CD8^+^ T cell depletion had no observable effect on *M.tb* burden in the lung and spleen of mice vaccinated with the vehicle control ([Fig. 5C](#F5){ref-type="fig"}), confirming that CD8^+^ T cells are not a major contributor at this stage of primary *M.tb* infection ([@R18];[@R19]). CD8^+^ T cell depletion also had no effect on *M.tb* burden in the lung and spleen of mice that had received the NaCl-exposed BCG vaccination ([@R20]). However, in contrast to the NaCl-exposed BCG group, CD8^+^ T cell depletion of mice that had been vaccinated with ALF-exposed BCG lost the enhanced capacity to control *M.tb* infection ([Fig. 5C](#F5){ref-type="fig"}), restoring *M.tb* burden to that of NaCl-exposed BCG. These data demonstrate that activation and expansion of CD8^+^ T cells by ALF-exposed BCG is directly responsible for the enhanced protection induced by ALF-exposed BCG.

We also analyzed the levels of IFNγ and IL-12p40 in the lung of vaccinated and *M.tb* infected mice with or without CD8^+^ T cell depletion. Results showed significant increases in IFNγ in the lungs of mice vaccinated with both NaCl- and ALF-exposed BCG ([Fig. 5D](#F5){ref-type="fig"}), but the highest level of IFNγ were associated with ALF-exposed BCG vaccination. Similar to *M.tb* CFU, when ALF-BCG vaccinated mice were depleted of CD8^+^ T cells, IFNγ production in response to *M.tb* infection returned to levels comparable to NaCl-exposed BCG. These data identify CD8^+^ T cells and IFNγ as important contributors to the enhanced protection against *M.tb* challenge that is mediated by ALF-exposed BCG vaccination. We did not observe any differences in IL-12p40 between the vaccinated/CD8^+^ T cell depleted groups ([Fig. 5D](#F5){ref-type="fig"}), further supporting the concept that CD8^+^ T cells were a dominant source of IFNγ ([@R21]). Though we did not extend our neutralization studies to later stages of the disease, we can postulate that the reduction in pulmonary inflammation observed at later time-points of *M.tb* infection ([Fig. 2](#F2){ref-type="fig"}) is directly linked to early (and potentially extended) CD8^+^ T cell activity in the lung.

Discussion {#S7}
==========

Host immune responses to *M.tb* and the requirements for its control have been well studied ([@R22]), yet immune mechanisms that result in efficient *M.tb* clearance from the host remain unknown. Here we show that vaccination with ALF-exposed BCG reduced early *M.tb* bacterial burden in the lung and spleen with superior control to that of conventional (NaCl-exposed) BCG. We purposefully chose an early time point as we predicted that ALF exposure of BCG would accelerate the control of *M.tb*, which is evident at day 14. ALF exposed BCG provided almost 1.0 Log~10~ protection at day 14, whereas unexposed BCG only provided modest protection at this time point, supporting our prediction and hypothesis. Importantly, at later stages of *M.tb* infection, mice vaccinated with ALF-exposed BCG retained the significantly lower bacterial burden in the lung and spleen compared to vehicle control, had reduced pulmonary inflammation in the lung, and extended host survival. These data support the concept that vaccine formulations capable of rapidly containing *M.tb* following infection are the most efficacious ([@R23];[@R24]), where earlier control of *M.tb* infection can translate into a reduction in pulmonary inflammation and *M.tb* bacterial burden at later stages and prolonged survival. We extend on this concept by implementing a vaccine strategy that is directed against the phenotype of *M.tb* within the lung ALF, and demonstrate a clear enhancement of BCG protective efficacy.

We extended our findings by establishing that CD8^+^ T cells make an important contribution to the degree of protection observed in ALF-exposed BCG vaccinated mice throughout the first 14 days, with CD8^+^ T cell depletion reverting ALF-exposed BCG protection (CFUs) back to that seen in mice vaccinated with NaCl-exposed BCG. Indeed, ALF-exposed BCG vaccination leads to increased numbers of activated (CD69^+^) CD8^+^ T cells within the lung, both CD8^+^ T cells displaying a memory phenotype and CD8^+^ T cells with the potential to secrete IFNγ in the lungs after *M.tb* challenge. This was further corroborated with our depletion CD8^+^ T cells studies which resulted in a reduction of IFNγ levels in the lung. We anticipate that these activated CD8^+^ T cells become resident memory CD8^+^ T cells forming a reservoir that responds quickly to *M.tb* ([@R25]).

The reduction of bacterial burden in the lung and spleen of *M.tb-*infected mice receiving the ALF-exposed BCG vaccine was likely mediated by CD8^+^ T cell derived IFNγ, as IFNγ concentrations in the lung was directly dependent on the presence or absence of CD8^+^ T cells despite similar numbers of CD4^+^ T cells in the lung. IFNγ is essential for the development of mycobacterial immunity ([@R26];[@R27]), and CD8^+^ T cell derived IFNγ has been previously shown to be important for protective immunity against *M.tb* infection ([@R21]).

We speculate that the reason why ALF-exposed BCG is better at priming CD8^+^ T cells may be via mechanisms that promote macrophage bacterial killing and/or enhance antigen presentation ([@R9]). Our biochemical analyses reveal that, similar to *M.tb* ([@R9]), exposure to ALF partially removes ManLAM and TDM from the BCG cell wall surface. TDM is the most abundant and toxic glycolipid on the BCG cell wall and ManLAM is the most abundant lipoglycan. TDM impairs the development of adaptive immune responses by blocking the process of phagosome maturation, by decreasing the expression of MHCII, CD40, CD80, and CD1d on macrophages, and by inhibiting macrophage-induced IL-12p40 \[reviewed in ([@R28])\], a key cytokine required for IFNγ secretion by T cells. Moreover, through the macrophage mannose receptor ManLAM limits phagosome maturation ([@R29]) and activates PPARγ modulating the macrophage inflammatory response ([@R30]). ManLAM also downregulates the oxidative burst and inhibits *M.tb* induced-apoptosis \[reviewed in ([@R28])\]. Thus; ManLAM, as TDM, could alter T cell proliferation and production of T cell derived IFNγ by downregulating macrophage innate immune responses. Hence, surface removal of TDM and ManLAM from BCG by exposure to ALF could partially explain the improved adaptive immune response observed. Moreover, components of the complement system are also produced by alveolar epithelial cells ([@R31]) and macrophages in the lung ([@R32]). It is reasonable to predict that the combination of ALF hydrolase-derived modifications and cell wall coating of ALF-soluble components (Complement, surfactant proteins, etc.) may play a role in the observed phenotype. Indeed, soluble components of serum such as complement can bind BCG ([@R33]), and thus potentially modify its interaction with the host. Whether complement deposition is the reason for increased protective efficacy of ALF treated BCG is a current line of research in our lab.

The functionality of CD8^+^ T cells in BCG vaccination has not been thoroughly addressed ([@R34]). A recent study showed that direct inoculation of BCG into the mouse lung generated protective CD8^+^ T cell resident memory cells ([@R35]). Our observations are in agreement with this finding wherein we attained a similar phenotype by subcutaneous administration of ALF-exposed BCG, which was simultaneously capable of reducing lung tissue damage. The mechanism(s) behind how CD8^+^ T cells contribute to the efficacy of ALF-exposed BCG could be through their cytotoxic function ([@R36]-[@R38]), their ability to stimulate other cells via secretion of specific immunomodulators ([@R38]), and/or their ability to induce apoptosis of cells via the FasL-Fas pathways targeting cells expressing Fas ([@R39]). Any of these mechanisms could lead to the early *M.tb* control we observed, and we can also speculate that they contribute to the extended control of *M.tb* infection and reduced pulmonary inflammation that are observed as CD8^+^ T cells have typically been associated with containment of *M.tb* infection ([@R40]).

It is well established that CD4^+^ T cells mediate 0.5-1 log~10~ reduction in *M.tb* bacterial burden in the lung and spleen of conventional BCG vaccinated mice ([@R41]). Indeed, depletion of CD8^+^ T cells did not restore *M.tb* CFU of NaCl- and ALF-exposed BCG to that of vehicle control mice, suggesting that CD4^+^ T cells mediated the CFU reduction observed between vehicle and NaCl-exposed BCG vaccinated mice. We did not directly assess through depletion studies whether CD4^+^ T cells contributed to the additional reduction in bacterial burden associated with ALF-exposed BCG vaccination because we did not observe any significant differences in CD4^+^ T cell activation status. Likewise, we cannot completely rule out a role for protective antibodies and/or B cell responses ([@R42]). It is possible that ALF treatment could reveal alternate and protective B cell epitopes on BCG. Overall, our data support an important role for CD8^+^ T cells in the control of *M.tb*. In this context, CD8^+^ T cells may be important mediators during the immediate immune response to *M.tb* in humans.

In addition to altering early immune events in the lung, ALF-exposed BCG vaccination reduced disease manifestations. We observed minor increases in lung cell infiltration at earlier stages of infection in mice vaccinated with NaCl and ALF-exposed BCG compared to vehicle control. Although changes did not reach significance, we attribute this to the development of immunological memory that allows for rapid responses to infection ([@R43]), and the expansion of an early and protective response to *M.tb* infection in vaccinated mice. Of more interest however, was the significant decrease in lung inflammation in mice that were vaccinated with ALF-exposed BCG at later stages of infection (250 DPI). ALF-exposed BCG vaccination led to a greater reduction in tissue involvement and inflammation when compared to vehicle and conventional BCG vaccinated animals. It is feasible that the early recruitment of IFNγ^+^CD8^+^ T cells induced by ALF-exposed BCG vaccination may have simply reduced *M.tb* infection to low enough levels to induce less inflammation, but it is equally plausible that long term control may have been a more active process. The relevance of reduced lung inflammation in mice vaccinated with ALF-exposed BCG relative to conventional BCG is currently unknown. We can associate it with the extended survival observed, although this is not an exact extrapolation because survival between mice vaccinated with ALF-exposed BCG was extended by only an additional 6 weeks compared to mice vaccinated with conventional (NaCl-exposed) BCG \[the equivalent of about 3-5 years extended life in humans ([@R44])\]. It is plausible that reduced pathology could also lead to altered morbidity, although these have not been directly studied, or simply reflect the limitations of working in the mouse model. Survival times varied within experimental groups by as much as 20 weeks; however, the distribution of survival observed is similar to what has been reported in the literature for C57BL/6J mice and is consistent across replicated experiments ([@R45]).

We recognize that we introduced some variability into our studies by using different human ALF samples in each experiment. As an example is the protection from the NaCl-exposed BCG group at 14 DPI in [Fig. 5C](#F5){ref-type="fig"} compared to that in [Fig. 1A](#F1){ref-type="fig"}. While we used the same human donor ALF for BCG and *M.tb* exposures (paired exposures in each 'n' value) prior to vaccination and infection (to ensure the same effects to the BCG and *M.tb* cell wall), each experiment was performed using a different human donor ALF to positively introduce human donor difference as an experimental variable (while working in an inbred mouse strain). We have previously published that ALF derived from different humans have slight different effects on *M.tb* ([@R9]) resulting from variability in the amount of certain innate immune proteins (*e.g.* surfactant proteins, complement proteins, alveolar hydrolases) present within ALF among humans \[([@R10]) and unpublished observations\]. Furthermore, as opposed to using frozen stocks of pre-calculated bacterial concentrations, we always generate single cell suspensions of *M.tb* from freshly agar-plate grown bacteria to ensure that the mycobacterial cell wall remains intact. Indeed, growth in liquid medium has been shown to affect the presence/absence and abundance of certain cell wall molecules ([@R46]). Hence, it is important to recognize that even with the introduction of variability into our *in vivo* experimental system we were able to generate reproducible findings within and across experiments using BCG and *M.tb* exposed to different human ALFs, including our results in an independent mouse strain (C3HeB/FeJ) that has a different susceptibility to *M.tb* infection.

In summary, human ALF contains an array of enzymes that modify the *M.tb* cell wall ([@R9];[@R14]), which we hypothesize impact *M.tb* uptake by phagocytic cells ([@R9];[@R13];[@R14];[@R47]) influencing the generation of adaptive immunity. In support of this, exposure of BCG to ALF increased the efficacy of BCG vaccination in terms of reducing bacterial burden and pulmonary inflammation, and the generation of CD8^+^ T cells that are required for the increased efficacy of ALF-exposed BCG. Hence our data demonstrate that human ALF exposure of BCG improves efficacy against *M.tb* challenge, and suggest that manipulation of BCG, particularly with emphasis on its cell wall composition during infection within the lung, offers novel avenues to understand and improve on the development of protective immunity to mycobacteria. Furthermore, our data support that targeting the production of early and rapid CD8^+^ T cell responses in the lung may be important for containment of *M.tb*.

Materials and Methods {#S8}
=====================

Ethics statement {#S9}
----------------

All experimental procedures with animals were approved by The Ohio State University Institutional Animal Care and Use Committee (IACUC protocol number: 2012A00000132-R1). For human subjects (to obtain BALF), this study was carried out in strict accordance with US Code of Federal and Local Regulations \[University Human Subjects Institutional Review Board (IRB) protocol number: 2008H0135\], and Good Clinical Practice as approved by the National Institutes of Health/National Institute of Allergies and Infectious Diseases/Division of Microbiology and Infectious Diseases (NIH/NIAID/DMID protocol number: 12-0086). In this study only adult human subjects participated, and all of them provided written informed consent.

Mice {#S10}
----

Specific- pathogen-free, female mice aged 6-8 weeks of the C57BL/6J or C3HeB/FeJ background were purchased from Jackson Laboratories (Bar Harbor, ME). Upon arrival, mice were supplied with sterilized water and chow *ad libitum* and acclimatized for at least one week prior to experimental manipulation. Mice were maintained in micro-isolator cages located in either a standard vivarium for all noninfectious studies or in a biosafety level three (ABSL-3) core facilities for all studies involving *M.tb*. Mice were divided into three groups: Mock-vaccinated (vehicle), NaCl-exposed BCG-vaccinated, or ALF-exposed BCG-vaccinated.

Growth conditions of M.tb and M. bovis BCG strain Pasteur {#S11}
---------------------------------------------------------

GFP*-M.tb* Erdman (provided by Dr. Horwitz, UCLA, CA) and *M. bovis* BCG Pasteur strains \[American Type Culture Collection (ATCC), \#35734\] were grown as previously described ([@R9];[@R13];[@R14];[@R47]).

Collection of human ALF and exposure to bacteria {#S12}
------------------------------------------------

Human ALF was obtained was obtained from human bronchoalveolar lavage fluid (BALF), concentrated to its physiological concentration within the human lung, and single cell suspensions of *M.tb* were exposed to human ALF as we previously reported ([@R9];[@R13];[@R14]). Bacteria were then washed with 0.9% NaCl to remove ALF and suspended at working concentrations for aerosol infections or subcutaneous injections with *M.tb* or *M. bovis* BCG, respectively.

Vaccination {#S13}
-----------

Mice were subcutaneously injected in the scruff of the neck with 100 μl of 0.9% NaCl (saline, vehicle), 0.9% NaCl-exposed, or ALF-exposed *M. bovis* BCG Pasteur (7.5×10^5^ CFU), diluted in sterile 0.9% NaCl. Mice were housed without further experimental manipulation for six weeks.

M.tb aerosol infection and colony forming unit enumeration {#S14}
----------------------------------------------------------

Mice were infected aerogenically with a low dose of *M.tb* using the Glas-Col (Terre Haute, IN) inhalation exposure system as previously described ([@R48]). Bacterial burden was assessed at various DPI by culturing serial dilutions of organ homogenates onto Middlebrook 7H11 agar supplemented with OADC as we have previously described ([@R48]). Colonies were enumerated following 14-21 days incubation at 37°C. Data are expressed as the log~10~ value of the mean number of CFU recovered per organ (n=4--5 mice). Lung homogenate were also plated onto OADC supplemented 7H11 agar containing 2 μg/ml of 2-thiophenecarboxylic acid hydrazide (TCH; Sigma-Aldrich) to exclude and differentiate BCG growth from *M.tb* ([@R49]). Mice in survival studies were monitored over a period of 85 weeks. Mice were euthanized following a body condition scoring system (BCS) ranging from 1 (emaciation) to 5 (obesity). Scores were determined by weekly visual and hands-on examination of each animal. Mice were euthanized when they reached a BCS of 2 or less ([@R50]).

Lung cell isolation {#S15}
-------------------

Lung cells were isolated as previously described ([@R51]). For specific details, see [supplemental materials](#SD1){ref-type="supplementary-material"}.

Immunophenotyping by flow cytometry {#S16}
-----------------------------------

Lung cell were prepared for flow cytometry as previously described ([@R51]). For specific details, see [supplemental materials](#SD1){ref-type="supplementary-material"}.

ELISA {#S17}
-----

Organ homogenates were analyzed for levels of IFNγ and IL-12p40 by ELISA following manufacturer\'s instructions (BD OptEIA) ([@R52]). ELISAs were read on a Spectramax M2 Microplate reader (Molecular Devices LLC, Sunnyvale, California). Surface ManLAM and TDM detection in whole bacteria after exposure to NaCl or human ALF is described in the supplemental section.

Cell depletion {#S18}
--------------

Cells depletions were performed as previously described ([@R52]). Briefly, 500 μg anti-CD8^+^ (Clone: 53.6.72) depletion antibody (BioXCell, West Lebanon, NH) or whole rat IgG2a (Clone: 2A3) (BioXCell) in 100 μl were injected into the intraperitoneal (i.p.) cavity four times over a period of two weeks beginning one day prior to *M.tb* challenge. Lungs were digested to obtain whole lung cells and stained with fluorophore conjugated antibodies for flow cytometry analysis to confirm CD8^+^ T cell depletion.

Histology {#S19}
---------

The middle right lung was isolated from each individual mouse and inflated with and stored in 10% neutral buffered formalin. Lung tissue was processed, sectioned, and stained with Hematoxylin and eosin for light microscopy with lobe orientation designed to allow for maximum surface area of each lobe to be seen. Sections were examined in a blinded manner by a board-certified veterinary pathologist without prior knowledge of the experimental groups and evaluated according to severity, granuloma size and number, cellular composition, lymphocytic cuffing, and necrosis. Areas of cell aggregation were quantified using Aperio Imagescope at 4× magnification by calculating the total area of the involved tissue over the total area of the lobe for each individual mouse.

Total Lipid extraction, thin layer chromatography and densitometry analysis of TDM {#S20}
----------------------------------------------------------------------------------

For in detail methodology see supplemental information.

Statistical analysis {#S21}
--------------------

Statistical significance was determined using Prism 4 software (GraphPad Software, San Diego, CA). The unpaired, two-tailed Student\'s t-test was used for two group comparisons. Multiple comparisons were analyzed using one-way ANOVA with Tukey\'s post-test. Log-Rank test was used to determine statistical significance of survival experiments. Statistical significance was reported as \**p*\<0.05; \*\**p*\<0.01; or \*\*\**p*\<0.001.

Supplementary Material {#S22}
======================

###### 

Figure S1. **ALF-exposed *M.tb* growth in the lung of infected C57BL/6J mice**. *M.tb* strain Erdman was exposed to different human ALFs for 12 h at 37°C, 5% CO~2~. Six to eight week old C57BL/6J mice were infected with a low dose aerosol calculated to deliver 40-100 viable *M.tb* bacilli to the lung. Groups of mice were sacrificed at 0 days post infection to quantitate the infection inoculum in the lung. CFUs were determined at 4, 21, 60, 150 and 250 days post infection by plating serial dilutions of lung homogenates. Pooled experiment from n=6 with 4-5 mice per group per time-point studied.

Figure S2. **ALF strips TDM and ManLAM from the BCG cell wall**. (**A**) Whole bacteria ELISA using NaCl- or ALF-exposed BCG and anti-ManLAM mAb CS-35 or anti-TDM polyclonal Ab. Pooled data of n*=*6, each experiment performed in duplicate, mean ± SEM; Student\'s *t*-test, \*\* *p*\<0.01. Purified ManLAM (5 μg) or TDM (5 μg) were included as positive control. (**B**) Thin layer chromatogram (TLC) of NaCl- or ALF-exposed BCG lipid extracts, TDM is highlighted in the box. NaCl: 1 and 2 correspond to different experiments and exposures; ALF: 1 to 6 correspond to different experiments and exposures using a different human ALF each time. The TLC densitometry semi-quantitative analysis of TDM remaining on NaCl- or ALF-exposed BCG is also shown.

Figure S3. **Vaccination with ALF-exposed BCG reduces the number of inflammatory foci and lymphocytic cuffs in the lung of C57BL/6J vaccinated mice**. C57BL/6J mice were vaccinated with NaCl-exposed BCG (NaCl-BCG; grey bars) or ALF-exposed BCG (ALF-BCG; black bars), or left unvaccinated (vehicle; open bars). Six weeks later, mice were infected with a low dose aerosol of *M.tb*. At 14 and 250 DPI, C57BL/6J mice were sacrificed and lungs fixed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin to visualize tissue morphology. The number of inflammatory foci and lymphocytic cuffs were quantified by a board certified immunopathologist. (**A, B**) At least 12 distinct lobes were examined from n=3 with 4-5 mice per group per time-point (C57BL/6J). (**C, D**) Five distinct lobes were examined from n=1 with 5 mice per group per time-point (C3HeB/FeJ). A representative lobe is pictured; pooled data, mean ± SEM; one-way ANOVA with Tukey\'s post-hoc test, \**p*\<0.05, \*\*\**p*\<0.001; ns: not significant.

Figure S4. **Vaccination with ALF-exposed BCG reduces *M.tb* bacterial burden in the lung and spleen of C3HeB/FeJ mouse strain and reduces pulmonary inflammation**. C3HeB/FeJ mice were vaccinated with NaCl-exposed BCG (NaCl-BCG; grey bars) or ALF-exposed BCG (ALF-BCG; black bars), or left unvaccinated (vehicle; open bars). Six weeks later, mice were infected with a low dose aerosol of *M.tb*. (**A**) C3HeB/FeJ mice were sacrificed at 14 and 100 days post infection and *M.tb* CFU determined in lung. (**B, C**) CFU data from n=1 with 5 mice per group per time-point, mean ± SEM, student\'s *t*-test, \**p*\<0.05; ns: not significant. (**D**) At 14 and 100 DPI, C3HeB/FeJ mice were sacrificed and their lungs were fixed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin to visualize tissue morphology. (**E, F**) Areas of cell aggregation (involvement) were quantified using Aperio Imagescope. Data are from n=1 with 5 mice per group per time-point, mean ± SEM; one-way ANOVA with Tukey\'s post-hoc test, \**p*\<0.05; ns: not significant. Notice that y-axis scales among some graphs are split different.

Figure S5. **Vaccination with ALF-exposed BCG preferentially stimulates CD8^+^ T-cells in the lung**. C57BL/6J mice were vaccinated with NaCl-exposed BCG (NaCl-BCG; white bars) or ALF-exposed BCG (ALF-BCG; black bars). Six weeks later, lungs were digested and single cell suspension of cells were labeled with fluorescent antibodies specific for CD8 or CD4 in combination with CD69, CD62L, CCR7, CD44, and intracellular IFNγ. (**A**) Percentage of CD8^+^ and CD4^+^ T cell in the lung. (**B**) Percent of CD8^+^ or CD4^+^ T cells with a memory (CD62L^+^CCR7^-^CD44^+^) phenotype. (**C**) Percent of CD8^+^ or CD4^+^ T cells with an effector (CD62L^-^CCR7^-^CD44^+^) phenotype. (**D**) Percent of CD8^+^ or CD4^+^ T cells with the potential to produce IFNγ. (**E**) Percent of CD8^+^ or CD4^+^ T cells expressing CD69. Representative experiment from n=2 with 5 mice per group, M ± SEM; Student\'s *t*-test comparing NaCl-BCG *vs.* ALF-BCG, \**p*\<0.05. Notice that y-axis scales among some graphs are split different.

Figure S6. **T cell responses in lung of vaccinated mice infected with *M.tb* at 14 DPI**. C57BL/6J were vaccinated with vehicle (open bars), NaCl-exposed BCG (NaCl-BCG; grey bars), or ALF-exposed BCG (ALF-BCG; black bars). Six weeks post vaccination, mice were challenged with *M.tb* and euthanized at 14 DPI to characterize immune cell populations in the lung by flow cytometry. (A) Percentage of CD8^+^ and CD4^+^ T cell in the lung. (B) Percent of CD8^+^ or CD4^+^ T cells with a memory (CD62L^+^CCR7^-^CD44^+^) phenotype. (C) Percent of CD8^+^ or CD4^+^ T cells with an effector (CD62L^-^CCR7^-^CD44^+^) phenotype. (D) Percent of CD8^+^ or CD4^+^ T cells with the potential to produce IFNγ. (E) Percent of CD8^+^ or CD4^+^ T cells expressing CD69. Representative experiment from n=2 with 5 mice per group, mean ± SEM; one-way ANOVA with Tukey\'s post-hoc test, \**p*\<0.05, \*\**p*\<0.01; ns: not significant. Notice that y-axis scales among some graphs are split different.

Figure S7. **Gating scheme of lymphocytes**. Lung lymphocytes were first gated based on their size (FSC) and granularity (SSC). Lymphocytes were split into CD4^+^ and CD8^+^ cells. Each lymphocyte subset (CD4^+^ or CD8^+^) was gated for CCR7^-^ negative cells. The CCR7^-^ gated cells were further sub-gated using CD62L and CD44. Within the gate, memory cells (CCR7^-^CD62L^+^CD44^+^) reside within Q2, while effector cells (CCR7^-^CD62L^-^CD44^+^) reside in Q3. In a second panel, each lymphocyte subset (CD4^+^ or CD8^+^) was gated for CD69. In a third panel, lung cells previously stimulated with CD3/CD28 were gated based on lymphocyte subset (CD4^+^ or CD8^+^) and gated for IFNγ.
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![Vaccination with ALF-exposed BCG reduces *M.tb* bacterial burden in the lung and spleen of C57BL/6J mice and extends survival\
C57BL/6J mice were vaccinated with NaCl-exposed BCG (NaCl-BCG; grey bars) or ALF-exposed BCG (ALF-BCG; black bars), or left unvaccinated (vehicle control; open bars). Six weeks later, mice were infected with a low dose aerosol of *M.tb*. (**A, B**) C57BL/6J mice were sacrificed at 14 and 250 days post infection and *M.tb* CFU determined in lung and spleen. Representative experiment from n=3 with 4-5 mice per group per time-point studied, mean ± SEM; one-way ANOVA with Tukey\'s post-hoc test, \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001; ns: not significant. (**C**) C57BL/6J mice were vaccinated with vehicle (open circles), NaCl-exposed BCG (grey diamonds) or ALF-exposed BCG (black circles) and challenged with *M.tb* six weeks later. Survival was monitored across a period of 85 weeks. Mice were euthanized when they met the exclusion criteria documented in animal care and use protocols. Mice in the vehicle group (n=15) displayed a mean survival of 50.00 weeks. NaCl-BCG (n=12) vaccinated mice had a mean survival of 64.50 weeks. ALF-BCG (n=18) vaccinated mice had a mean survival of 71.00 weeks. Pooled data from n=3 with 4-6 mice per group (12-18 total mice per group), mean ± SEM; Log-rank test, \*Vehicle *vs.* NaCl-BCG (*p*=0.0111), \*\*\*\*Vehicle *vs.* ALF-BCG (*p*\<0.0001), \*\*NaCl-BCG *vs.* ALF-BCG (*p*=0.0069). In all the experiments, for each 'n' value, ALFs from different donors were used.](nihms899605f1){#F1}

![Vaccination with ALF-exposed BCG reduces pulmonary inflammation in the *M.tb* infected lung of vaccinated mice\
C57BL/6J mice were vaccinated with NaCl-exposed BCG (NaCl-BCG; grey bars) or ALF-exposed BCG (ALF-BCG; black bars), or left unvaccinated (vehicle; open bars). Six weeks later, mice were infected with a low dose aerosol of *M.tb*. (**A**) At 14 and 250 DPI, C57BL/6J mice were sacrificed and lungs fixed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin to visualize tissue morphology. (**B, C**) Pulmonary inflammation was quantified using Aperio Imagescope. At least 12 distinct lobes were examined from n=3 with 4-5 mice per group per time-point in each experiment. A representative lobe is pictured; pooled data (involvement), mean ± SEM; one-way ANOVA with Tukey\'s post-hoc test, \**p*\<0.05, \*\*\**p*\<0.001; ns: not significant. In all the experiments, for each 'n' value, ALFs from different donors were used.](nihms899605f2){#F2}

![Vaccination with ALF-exposed BCG preferentially stimulates CD8^+^ T cells in the lung\
C57BL/6J mice were vaccinated with NaCl-exposed BCG (NaCl-BCG; white bars) or ALF-exposed BCG (ALF-BCG; black bars). Six weeks later, lungs were digested and single cell suspension of cells were labeled with fluorescent antibodies specific for CD8 or CD4 in combination with CD69, CD62L, CCR7, CD44, and intracellular IFNγ. (**A**) Total number of CD8^+^ and CD4^+^ T cell in the lung. (**B**) Total number of CD8^+^ or CD4^+^ T cells with a memory (CCR7^neg^CD62L^hi^ CD44^hi^) phenotype. (**C**) Total number of CD8^+^ or CD4^+^ T cells with an effector (CCR7^neg^CD62L^lo^ CD44^hi^) phenotype. (**D**) Total number of CD8^+^ or CD4^+^ T cells with the potential to produce IFNγ. (**E**) Total number of CD8^+^ or CD4^+^ T cells expressing CD69. The absolute number of T cells in the lung is shown. Pooled data from n=2 with 4-5 mice per group in each experiment, mean ± SEM; Student\'s *t*-test comparing NaCl-BCG *vs.* ALF-BCG, \**p*\<0.05. Notice that y-axis scales among graphs are split different. In all the experiments, for each 'n' value, ALFs from different donors were used.](nihms899605f3){#F3}

![Vaccination with ALF-exposed BCG enhances CD8^+^ T cell responses in lung of *M.tb* infected mice\
C57BL/6J were vaccinated with vehicle (open bars), NaCl-exposed BCG (NaCl-BCG; grey bars), or ALF-exposed BCG (ALF-BCG; black bars). Six weeks post vaccination, mice were challenged with *M.tb* and euthanized at 14 DPI to characterize immune cell populations in the lung by flow cytometry. (**A**) Total number of CD8^+^ and CD4^+^ T cell in the lung. (**B**) Total number of CD8^+^ or CD4^+^ T cells with a memory (CCR7^neg^CD62L^hi^ CD44^hi^) phenotype. (**C**) Total number of CD8^+^ or CD4^+^ T cells with an effector (CCR7^neg^CD62L^lo^ CD44^hi^) phenotype. (**D**) Total number of CD8^+^ or CD4^+^ T cells with the potential to produce IFNγ. (**E**) Total number of CD8^+^ or CD4^+^ T cells expressing CD69. Pooled experiment from n=2 with 4-5 mice per group, mean ± SEM; one-way ANOVA with Tukey\'s post-hoc test, \**p*\<0.05, \*\**p*\<0.01; ns: not significant. Notice that y-axis scales among graphs are split different. In all the experiments, for each 'n' value, ALFs from different donors were used.](nihms899605f4){#F4}

![Reduction in bacterial burden associated with ALF-exposed BCG is dependent on CD8^+^ T cell responses\
C57BL/6J mice were vaccinated with vehicle, NaCl-exposed BCG, or ALF-exposed BCG. Six weeks after vaccination, mice were i.p. injected with 500 μg of anti-CD8a, or rat IgG2a and challenged with *M.tb.* Anti-CD8a or rat IgG2a was delivered 1 day prior to *M.tb* challenge and every 4 days thereafter. Mice were sacrificed at 14 DPI. (**A**) Schematic depicting effective depletion of CD8^+^ T cells from the lung. (**B**) Quantification of CD8^+^ and CD4^+^ T cells in the lung of isotype-injected or anti-CD8a injected mice. CD8^+^ T cells were depleted to less than 20 cells per 50,000 cells. Depletion of CD8^+^ T cells did not affect the number of CD4^+^ T cells in the lung. Pooled experiment from n=2 with 5 mice/per group, mean ± SEM; student\'s-*t* test, \*\*\**p*\<0.001. (**C**) *M.tb* CFUs were determined in the lung and spleen at 14 DPI. Pooled experiment from n=2 with 5 mice/per group, mean ± SEM; one-way ANOVA with Tukey\'s post-hoc test or student\'s *t*-test (for single comparisons), \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001, ^§^*p*\<0.05, ^§§§^*p*\<0.01; ns: not significant. (**D**) IFNγ and IL-12p40 in the lung homogenates of vehicle-treated or vaccinated mice with or without CD8^+^ T cells depletion at 14 DPI. Representative experiment from n=2 with 5 mice/per group, mean ± SEM, one-way ANOVA with Tukey\'s post-hoc test (for multiple groups) or student\'s t-test (for single comparisons), \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001. In all the experiments, for each 'n' value, ALFs from different donors were used.](nihms899605f5){#F5}
